Welcome to our dedicated page for Artelo Biosciences news (Ticker: ARTL), a resource for investors and traders seeking the latest updates and insights on Artelo Biosciences stock.
Artelo Biosciences, Inc. develops clinical-stage therapeutics that modulate lipid-signaling pathways, including programs tied to the endocannabinoid system and fatty acid-binding proteins. Company news commonly covers pipeline updates for ART27.13 and ART26.12, including cancer anorexia-cachexia, neuropathic pain, glaucoma, dermatologic, neurological and other inflammation-related indications.
Recurring developments include FABP5 inhibitor research, peer-reviewed publications, collaborations using biological-data analysis, preclinical and clinical program disclosures, patent activity, and externally funded studies. Artelo news also includes capital-structure actions such as private placements, common stock and warrant offerings, and Nasdaq listing-compliance matters.
Artelo Biosciences (Nasdaq: ARTL) reported Q1 2026 results and highlighted clinical milestones expected through 2027. The company is advancing ART26.12 in pain with positive Phase 1 single ascending dose and food-effect data and plans a multiple ascending dose study starting enrollment in Q4 2026.
ART27.13 showed encouraging interim Phase 2 CAReS data in cancer-related anorexia, with gains in body weight, lean body mass, and physical activity. Q1 2026 R&D expenses were $0.8M, G&A $1.9M, net loss $3.0M, and cash and investments $10.3M.
Artelo Biosciences (Nasdaq: ARTL) announced a strategic collaboration with AI company ScienceMachine to accelerate development of its FABP5 inhibitor program, including lead candidate ART26.12.
ScienceMachine applied AI to Artelo’s Phase 1 single ascending dose dataset (ART26.12-100) and multi-omic disease models, identifying candidate proteins indicative of FABP5 target engagement, dose-responsive protein and lipid signatures linked to analgesia, and psoriasis-model results planned for publication later in 2026.
Artelo (Nasdaq: ARTL) announced a peer‑reviewed publication in the European Journal of Pain supporting FABP5 inhibition and preclinical evidence for its candidate ART26.12 as a non‑opioid pain treatment. ART26.12 showed analgesic effects across multiple pain models and seven prior preclinical studies.
The company reported its Phase 1 single ascending dose study had no drug‑related severe or serious adverse events, and a multiple ascending dose study is planned for 2026.
Artelo Biosciences (Nasdaq: ARTL) announced Nasdaq has confirmed the company has regained compliance with Listing Rules 5550(b)(1) and 5620(a). The company held a reconvened annual meeting on January 30, 2026, and regained equity-rule compliance as noted in a March 30, 2026 filing.
In accordance with Listing Rule 5815(d)(4)(B), Artelo will be subject to a mandatory panel monitor for one year. Management reiterated focus on advancing clinical candidates ART27.13 and ART26.12 and pursuing partnership discussions.
Artelo Biosciences (Nasdaq: ARTL) closed a private placement on March 30, 2026, issuing 3,188,407 shares (or pre-funded warrants) and warrants to buy up to 6,376,814 shares at a combined price of $3.45 per share/warrant, generating approximately $11.0 million gross proceeds before fees.
The company intends to use net proceeds for working capital, general corporate purposes, and repayment of certain bridge debt. If all warrants are exercised for cash, potential additional gross proceeds could be about $20.4 million; exercise is not assured.
Artelo Biosciences (Nasdaq: ARTL) entered definitive agreements for a private placement expected to close on or about March 30, 2026. The offering comprises 3,188,407 common shares (or pre-funded warrants) and warrants to buy 6,376,814 shares at $3.20, at a combined purchase price of $3.45 per unit.
Gross proceeds are expected to be approximately $11.0 million before fees; warrants could generate approximately $20.4 million if fully exercised. H.C. Wainwright is exclusive placement agent. Net proceeds will fund working capital, general corporate purposes, and repayment of bridge debt.
Artelo Biosciences (NASDAQ: ARTL) announced expansion of development for ART27.13 as a potential companion therapy to GLP-1 treatments on March 25, 2026. Key actions include a provisional patent filing, initiation of a non‑clinical study, publication of independent research, and supportive CAReS trial observations.
The company cites improvements in lean body mass and preclinical reversal of myotoxicity, positioning ART27.13 for muscle preservation alongside rapidly growing GLP-1 use.
Artelo Biosciences (NASDAQ: ARTL) expands ART27.13 into the $16.3B glaucoma market via a fully funded investigator-sponsored trial while advancing three clinical programs in oncology support, neuropathic pain, and CNS disorders.
Key advantages: positive Phase 2 signals, MHRA guidance for ART12.11, FABP inhibitor Phase 1 safety, European patent protection to 2041, and a $25M equity facility.
Artelo Biosciences (NASDAQ: ARTL) is expanding into glaucoma with a fully funded investigator-sponsored trial evaluating ART27.13, with first patient enrollment expected in Q2 2026. The move diversifies the pipeline without shareholder dilution and leverages a peripherally selective CB2-targeting mechanism. Key milestones include ongoing Phase 2 CAReS data and a European patent extending protection through December 2041. The global glaucoma market is projected to reach USD 16.31 billion by 2033, underscoring the commercial opportunity while noting typical early-stage clinical and regulatory risks.
Artelo Biosciences (Nasdaq: ARTL) entered a definitive investigator-initiated study agreement with Belfast Health and Social Care Trust to evaluate oral ART27.13 in glaucoma and ocular hypertension. The pilot, randomized cross-over study is funded by Glaucoma UK and HSC R&D, has ethics and MHRA approval, and expects first patient enrollment in Q2 2026. Artelo will supply ART27.13 capsules; the program tests a peripherally selective cannabinoid approach to lower intraocular pressure while avoiding central nervous system effects.